Toggle navigation
Home
Search
Services
Blog
Contact
About
Early Therapeutics Development with Phase II Emphasis
Search grants from
Share this grant:
:
:
Abstract
Funding
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Extraordinary responder cell lines reveal unique targetable genetic dependencies
Effects of Stereotype Threat on the Health-Related Outcomes of African Americans
Cardiac function and PIP2
Function of Foregut Endoderm in Cardiogensis
Rhodium(III) Complexes as Site-Specific DNA Probes
Recently added grants:
DOTA-based pre-targeting of alpha emitters
Role of HIV in acceleration of HPV malignancy
Targeting p38 gamma signaling to advance Cutaneous T Cell Lymphoma Therapy
Role of the gut microbiome in modulating the efficacy of checkpoint blockade therapy
Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM62201-5-0-2
Application #
7568588
Study Section
Project Start
2006-01-01
Project End
2008-12-31
Budget Start
Budget End
Support Year
Fiscal Year
2007
Total Cost
Indirect Cost
Related projects
NIH 2008
N01 CA
Early Therapeutics Development with Phase II Emphasis
/ University of Chicago
$662,981
NIH 2007
N01 CA
Early Therapeutics Development with Phase II Emphasis
Vokes, Everett E. /
$1,737,296
NIH 2007
N01 CA
Early Therapeutics Development with Phase II Emphasis
/
$1,737,296
NIH 2007
N01 CA
Early Therapeutics Development with Phase II Emphasis
/
Comments
Be the first to comment on this grant